PE20211752A1 - Formas y metodos de dosis para bupropion enantiomericamente enriquecido o puro - Google Patents
Formas y metodos de dosis para bupropion enantiomericamente enriquecido o puroInfo
- Publication number
- PE20211752A1 PE20211752A1 PE2020001272A PE2020001272A PE20211752A1 PE 20211752 A1 PE20211752 A1 PE 20211752A1 PE 2020001272 A PE2020001272 A PE 2020001272A PE 2020001272 A PE2020001272 A PE 2020001272A PE 20211752 A1 PE20211752 A1 PE 20211752A1
- Authority
- PE
- Peru
- Prior art keywords
- bupropion
- dosage forms
- enantiomerically enriched
- methods
- enriched
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862634718P | 2018-02-23 | 2018-02-23 | |
| US201962794469P | 2019-01-18 | 2019-01-18 | |
| US201962809480P | 2019-02-22 | 2019-02-22 | |
| PCT/US2019/019445 WO2019165379A1 (en) | 2018-02-23 | 2019-02-25 | Dosage forms and methods for enantiomerically enriched or pure bupropion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20211752A1 true PE20211752A1 (es) | 2021-09-06 |
Family
ID=67688503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020001272A PE20211752A1 (es) | 2018-02-23 | 2019-02-25 | Formas y metodos de dosis para bupropion enantiomericamente enriquecido o puro |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP3755312A4 (enExample) |
| JP (3) | JP2021513998A (enExample) |
| KR (3) | KR20240091043A (enExample) |
| CN (2) | CN120827545A (enExample) |
| AU (3) | AU2019223187B2 (enExample) |
| BR (1) | BR112020017179A2 (enExample) |
| CA (1) | CA3092076A1 (enExample) |
| CL (1) | CL2020002166A1 (enExample) |
| CR (1) | CR20200415A (enExample) |
| EC (1) | ECSP20060179A (enExample) |
| IL (2) | IL313368A (enExample) |
| MA (1) | MA51914A (enExample) |
| MX (2) | MX2020008704A (enExample) |
| MY (1) | MY202993A (enExample) |
| NI (1) | NI202000056A (enExample) |
| NZ (1) | NZ767378A (enExample) |
| PE (1) | PE20211752A1 (enExample) |
| SG (1) | SG11202008056SA (enExample) |
| WO (1) | WO2019165379A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021513998A (ja) * | 2018-02-23 | 2021-06-03 | アクスサム セラピューティクス インコーポレイテッド | 鏡像異性体的に濃縮された、または鏡像異性体的に純粋なブプロピオンの剤形 |
| US11660274B2 (en) | 2018-09-20 | 2023-05-30 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| US11291639B2 (en) | 2018-09-20 | 2022-04-05 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| US11660273B2 (en) | 2018-09-20 | 2023-05-30 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| MX2022003346A (es) * | 2019-09-20 | 2022-04-11 | Axsome Therapeutics Inc | Formas de dosificacion y metodos para bupropion enantiomericamente enriquecido o puro. |
| US11717518B1 (en) | 2022-06-30 | 2023-08-08 | Antecip Bioventures Ii Llc | Bupropion dosage forms with reduced food and alcohol dosing effects |
| US12156914B2 (en) * | 2022-06-30 | 2024-12-03 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising bupropion and cysteine |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2483499A (en) * | 1998-01-29 | 1999-08-16 | Sepracor, Inc. | Pharmaceutical uses of optically pure (+)-bupropion |
| US6337328B1 (en) * | 1999-03-01 | 2002-01-08 | Sepracor, Inc. | Bupropion metabolites and methods of use |
| BRPI0318456B8 (pt) * | 2003-08-08 | 2021-05-25 | Biovail Laboratories Int Srl | tablete com liberação modificada |
| WO2012118562A1 (en) * | 2011-03-02 | 2012-09-07 | Rhine Pharmaceuticals, Llc | Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations |
| US10080727B2 (en) * | 2013-11-05 | 2018-09-25 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| US9198905B2 (en) * | 2013-11-05 | 2015-12-01 | Antecip Bioventures Ii Llc | Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects |
| US9474731B1 (en) * | 2013-11-05 | 2016-10-25 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| WO2015095713A1 (en) * | 2013-12-20 | 2015-06-25 | Deuterx, Llc | Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion |
| JP2021513998A (ja) * | 2018-02-23 | 2021-06-03 | アクスサム セラピューティクス インコーポレイテッド | 鏡像異性体的に濃縮された、または鏡像異性体的に純粋なブプロピオンの剤形 |
-
2019
- 2019-02-25 JP JP2020544420A patent/JP2021513998A/ja active Pending
- 2019-02-25 CA CA3092076A patent/CA3092076A1/en active Pending
- 2019-02-25 PE PE2020001272A patent/PE20211752A1/es unknown
- 2019-02-25 MX MX2020008704A patent/MX2020008704A/es unknown
- 2019-02-25 MA MA051914A patent/MA51914A/fr unknown
- 2019-02-25 BR BR112020017179-4A patent/BR112020017179A2/pt unknown
- 2019-02-25 AU AU2019223187A patent/AU2019223187B2/en active Active
- 2019-02-25 KR KR1020247017593A patent/KR20240091043A/ko active Pending
- 2019-02-25 EP EP19756920.5A patent/EP3755312A4/en active Pending
- 2019-02-25 IL IL313368A patent/IL313368A/en unknown
- 2019-02-25 NZ NZ767378A patent/NZ767378A/en unknown
- 2019-02-25 KR KR1020207027256A patent/KR20210003091A/ko not_active Ceased
- 2019-02-25 IL IL276871A patent/IL276871B2/en unknown
- 2019-02-25 CR CR20200415A patent/CR20200415A/es unknown
- 2019-02-25 WO PCT/US2019/019445 patent/WO2019165379A1/en not_active Ceased
- 2019-02-25 CN CN202510967625.3A patent/CN120827545A/zh active Pending
- 2019-02-25 MY MYPI2020004315A patent/MY202993A/en unknown
- 2019-02-25 KR KR1020237017449A patent/KR20230075531A/ko not_active Ceased
- 2019-02-25 SG SG11202008056SA patent/SG11202008056SA/en unknown
- 2019-02-25 CN CN201980026874.5A patent/CN112087999A/zh active Pending
-
2020
- 2020-08-20 MX MX2023009281A patent/MX2023009281A/es unknown
- 2020-08-21 NI NI202000056A patent/NI202000056A/es unknown
- 2020-08-21 CL CL2020002166A patent/CL2020002166A1/es unknown
- 2020-09-23 EC ECSENADI202060179A patent/ECSP20060179A/es unknown
-
2022
- 2022-06-27 AU AU2022204521A patent/AU2022204521B2/en active Active
- 2022-08-04 JP JP2022124557A patent/JP2022153638A/ja active Pending
-
2024
- 2024-03-15 JP JP2024041381A patent/JP2024075655A/ja active Pending
- 2024-08-17 AU AU2024205858A patent/AU2024205858A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL276871B2 (en) | 2024-11-01 |
| JP2024075655A (ja) | 2024-06-04 |
| AU2019223187B2 (en) | 2022-07-28 |
| KR20210003091A (ko) | 2021-01-11 |
| MX2020008704A (es) | 2020-12-07 |
| CR20200415A (es) | 2021-02-03 |
| MY202993A (en) | 2024-05-31 |
| AU2022204521B2 (en) | 2024-09-05 |
| IL276871B1 (en) | 2024-07-01 |
| AU2022204521A1 (en) | 2022-07-21 |
| CN112087999A (zh) | 2020-12-15 |
| CL2020002166A1 (es) | 2020-10-23 |
| AU2019223187A1 (en) | 2020-09-17 |
| NZ767378A (en) | 2024-03-22 |
| CN120827545A (zh) | 2025-10-24 |
| KR20230075531A (ko) | 2023-05-31 |
| SG11202008056SA (en) | 2020-09-29 |
| MA51914A (fr) | 2020-12-30 |
| JP2021513998A (ja) | 2021-06-03 |
| NI202000056A (es) | 2021-01-11 |
| EP3755312A1 (en) | 2020-12-30 |
| JP2022153638A (ja) | 2022-10-12 |
| WO2019165379A1 (en) | 2019-08-29 |
| KR20240091043A (ko) | 2024-06-21 |
| MX2023009281A (es) | 2023-08-17 |
| CA3092076A1 (en) | 2019-08-29 |
| AU2024205858A1 (en) | 2024-09-05 |
| BR112020017179A2 (pt) | 2020-12-22 |
| ECSP20060179A (es) | 2020-12-31 |
| EP3755312A4 (en) | 2022-03-16 |
| IL276871A (en) | 2020-10-29 |
| IL313368A (en) | 2024-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20211752A1 (es) | Formas y metodos de dosis para bupropion enantiomericamente enriquecido o puro | |
| MX2020012966A (es) | Combinacion, composicion y preparacion de combinacion farmaceutica que comprende activador de glucocinasa e inhibidor de sglt-2, metodos de preparacion y usos de las mismas. | |
| CL2020001742A1 (es) | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades | |
| GT201600137A (es) | Formulación compuesta para administración oral que comprende ezetimibe y rosuvastatina | |
| CL2022001178A1 (es) | Ligandos de la pseudoquinasa tyk2 | |
| MX2016010235A (es) | Composicion farmaceutica que comprende eritrocitos que encapsulan una enzima dependiente de fosfato de piridoxal (plp) y su cofactor. | |
| MX2019014113A (es) | Terapia combinada para trastornos neuropsiquiatricos sensibles al antagonista de nmdar. | |
| CL2021000030A1 (es) | Uso de estimuladores de la sgc para el tratamiento de trastornos mitocondriales | |
| WO2020061486A3 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| BR112015023761A2 (pt) | moduladores de molécula pequena de pcsk9 e seus métodos e usos | |
| MX2021008432A (es) | Composiciones farmaceuticas y usos dirigidos a los trastornos del almacenamiento lisosomal. | |
| CL2020003143A1 (es) | Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitario para el tratamiento de una enfermedad parasitaria | |
| MX376249B (es) | Derivados de etinilo. | |
| ECSP17022124A (es) | Composición farmacéutica sólida que comprende amlodipino y losartán | |
| BR112018074434A2 (pt) | composições farmacêuticas compreendendo safinamida | |
| MX2016014740A (es) | Un metodo para el tratamiento de trastornos del movimiento con befiradol. | |
| MY198201A (en) | A Combination Medicament Comprising Phenylephrine And Paracetamol | |
| NZ786429A (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| ECSP19048402A (es) | Compuestos de ácido ascórbico y quinona para el tratamiento de la enfermedad de chagas | |
| CL2021000022A1 (es) | Composición farmacéutica que contiene un péptido | |
| Heym | Musculoskeletal pain: 8 case reports | |
| CO2019008347A2 (es) | Composición de liberación rápida de cinitaprida y simeticona y proceso para prepararla | |
| Schiffman | Constipation and mild sedation: case report | |
| CL2004001039A1 (es) | Iso de modafinilo y un antidepesivo seleccionado del grupo que incluye triciclicos, inhibidores selectivos de la recaptacion de serotonna, inhibidores de la recaptacion de serotonina y nordrenalina, inhibidores de la mao y mao tipo a para preparar un | |
| MX2015016506A (es) | Una mezcla enriquecida con la estereoquimica r,r de 3',4'-di-o-acetil-cis-quelactona para el tratamiento de la diabetes mellitus. |